GO
Loading...

Worldwide Exchange

More

  • AstraZeneca has the "critical mass" to succeed internationally, Pascal Soriot, CEO of AstraZeneca told CNBC, also discussing the group¿s pipeline.

  • Pfizer suffering from patent cliff: Pro     Tuesday, 13 May 2014 | 5:50 AM ET

    Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.

  • Ian Read, CEO of Pfizer, says there is a "very strong industrial rationale" behind its AstraZeneca's takeover bid, as the groups' pipelines would both benefit from being combined.

  • Why you should favour large-caps     Tuesday, 13 May 2014 | 5:30 AM ET

    Andrew Burkly, head of institutional portfolio strategy at Oppenheimer & Co., says the underlying fundamentals for U.S. equities remain "pretty constructive", and large cap stocks should outperform small caps this year.

  • Gas shouldn't be used 'as a weapon': OMV CEO     Tuesday, 13 May 2014 | 5:10 AM ET

    Gerhard Roiss, CEO of OMV, discusses the impact of the Russian sanctions on European gas, and dismisses calls for a unified gas price across the region.

  • Pfizer 'aggressive' in cutting costs: Pro     Tuesday, 13 May 2014 | 5:00 AM ET

    Scott Moeller, director of the M&A research centre at Cass Business School, discusses the potential AstraZeneca takeover and Pfizer's strategy.

  • 'Brand EU' not strong enough: Expert     Tuesday, 13 May 2014 | 4:40 AM ET

    Nicolas De Santis, president and secretary general at Gold Mercury International, says the European Union has an "identity problem" and needs a stronger brand and identity.

  • Sell in May and go away? Not for EM credit!     Tuesday, 13 May 2014 | 4:30 AM ET

    Christian Keller, head of emerging markets research at Barclays, says emerging market credit valuation is quite attractive but advises being "choosy and picky."

  • UK needs more 'long-termism': Opposition     Tuesday, 13 May 2014 | 4:00 AM ET

    Chuka Umunna, U.K. shadow business secretary, says the potential AstraZeneca takeover by Pfizer should be looked at as of national economic interest, and that more should be done to protect R&D jobs.

  • AstraZeneca takeover would be good for UK: Pro     Tuesday, 13 May 2014 | 4:00 AM ET

    Ranjith Gopinathan, program manager for life sciences and health care practice at Frost & Sullivan, explains why he believes the Pfizer/AstraZeneca deal would be positive.

  • Where to invest in equities     Monday, 12 May 2014 | 5:30 AM ET

    Mebane Faber, CIO of Cambria Investment Management, discusses where to get the best-value equities now there are a lot of "very cheap" countries.

  • EU won't recognize Ukrainian vote: Minister     Monday, 12 May 2014 | 5:14 AM ET

    The European Union will not recognize the "pseudo-referendum" in eastern Ukraine says Radoslaw Sikorski, Polish foreign minister, adding that it also refuses to recognize the annexation of Crimea.

  • Pfizer 'back on the attack'     Monday, 12 May 2014 | 5:05 AM ET

    Pfizer is "back on the attack" and trying to make sure the takeover of AstraZeneca is seen as being "all about science and medicine", CNBC's Catherine Boyle reports.

  • M&A: Investors ready to 'punish'     Monday, 12 May 2014 | 5:00 AM ET

    Michael O'Sullivan, CIO for U.K. and EMEA at Credit Suisse Private Bank, discusses M&A activity and says it's now "running into reality" as governments, shareholders and investors are becoming more vocal.

  • Sharp facing 'difficult times': Pro     Monday, 12 May 2014 | 4:40 AM ET

    Atul Goyal, senior analyst at Jefferies, says Sharp is facing intensifying competition, warning that the group will need to raise "a lot of equity" in the coming year.

  • 'Bearish reversal' for the euro?     Monday, 12 May 2014 | 4:30 AM ET

    John Hardy, foreign exchange strategist at Saxo Bank, says there's a "bearish reversal" for the euro, which could slip lower ahead of the ECB June meeting.

  • Ukraine: 'No dramatic reaction' from markets     Monday, 12 May 2014 | 4:00 AM ET

    Antonin Jullier, global head of equity trading strategy at Citi, says global stock markets are "getting used" to the situation in Ukraine and discusses investing in equities.

  • Why Apple might acquire Beats     Friday, 9 May 2014 | 5:30 AM ET

    Richard Kramer, managing partner at Arete Research, discusses Apple's potential acquisition of Beats and says this could be a "very profitable" business.

  • NFL draft is 'extraordinary event': Expert     Friday, 9 May 2014 | 5:20 AM ET

    Robert Boland, academic chair and professor of sports management at NYU, comments on the NFL as the draft kicks off in New York on Friday.

  • Francesco Galietti, founder and CEO of Policy Sonar, says Silvio Berlusconi is likely to try and turn his community service into a political opportunity, and that his lack of official successor is hurting his Forza Italia party.

About Worldwide Exchange

  • CNBC's global business programme brings the business and investing world together. Each weekday Julia Chatterley considers the business stories that have global significance. With reports from CNBC's correspondents from around the world, Worldwide Exchange delivers essential, actionable information for any investor, anywhere who wants to be part of a global business conversation.

Contact Worldwide Exchange

  • Twitter: @CNBCWEX
  • Showtimes

    United States
    Monday - Friday 4a ET
    Europe
    Monday - Friday 10:00 CET
    Asia
    Monday - Friday 17:00 SIN/HK
    Australia
    Monday - Friday 20:00 SYD
    New Zealand
    Monday - Friday 22:00 NZ

 

  • Chatterley is CNBC’s European reporter covering key business and political events, as well as regular Eurogroup and EU leaders summits in Brussels.